Central Retinal Vein Occlusion Clinical Trial
Official title:
Study on Central Retinal Vein Occlusion Patients Receiving Bevacizumab and Dexamethasone or Bevacizumab Only on Naive Eyes.
The purpose of this study is to determine whether Bevacizumab (Avastin) in combination with Dexamethasone (Ozurdex) will be effective in reducing if not eliminating the macular edema associated with the disease, central retinal vein occlusion (CRVO) in comparison to Bevacizumab (Avastin) alone.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | September 17, 2021 |
Est. primary completion date | March 30, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Written informed consent must be obtained before any study assessment is performed 2. Diagnosis of visual impairment exclusively due to ME secondary to CRVO 3. BCVA score at Screening and Baseline between 73 and 19 letters (ETDRS) Exclusion Criteria: 1. Pregnant or nursing (lactating) women 2. Stroke or myocardial infarction less than 3 months before Screening 3. Uncontrolled blood pressure defined as systolic value of >160 mm Hg or diastolic value of >100 mm Hg at Screening or Baseline. 4. Any active periocular or ocular infection or inflammation at Screening or Baseline in either eye 5. Uncontrolled glaucoma at Screening or Baseline or diagnosed within 6 months before Baseline in either eye 6. Neovascularization of the iris or neovascular glaucoma in the study eye 7. Use of any systemic antivascular endothelial growth factor (anti-VEGF) drugs within 6 months before Baseline 8. Panretinal laser photocoagulation within 3 months before Baseline or anticipated or scheduled within the next 3 months following Baseline in the study eye 9. Focal or grid laser photocoagulation within 4 months before Baseline in the study eye 10. Use of intra- or periocular corticosteroids (including sub-Tenon) or ocular anti-VEGF treatment within 3 months before Screening in the study eye 11. Any use of intraocular corticosteroid implants (eg, dexamethasone [Ozurdex®], fluocinolone acetonide [Iluvien®]) in the study eye |
Country | Name | City | State |
---|---|---|---|
China | He Eye Specialist Hospital | Shenyang | Liaoning |
Lead Sponsor | Collaborator |
---|---|
He Eye Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean change in monocular BCVA in the treatment eye | Monocular BCVA in the treatment eye is assessed by using ETDRS visual acuity charts at 4 meters. | Baseline, 1 week, 1month, 2 months, 3 months, and 6 months. | |
Primary | Mean change in binocular BCVA | Binocular BCVA is assessed by using ETDRS visual acuity charts at 4 meters. | Baseline, 1 week, 1 month, 2 months, 3 months, and 6 months. | |
Secondary | Mean change in central subfield retinal thickness | Mean change in central subfield retinal thickness in the study eye, as determined by spectral domain optical coherence tomography (OCT). | Baseline, 1 week, 1 month, 2 months, 3 months, and 6 months. | |
Secondary | Change in Humphrey 10-2 visual field in the treatment eye | Mean deviation (MD) of the Humphrey 10-2 visual field is assessed by a Humphrey 10-2 visual field test. | Baseline, 1 week, 1 month, 2 months, 3 months, and 6 months. | |
Secondary | Number of Ranibizumab Treatments | Number of injections provided to the patients during the 6 month period. | Day 1 through Month 6 | |
Secondary | Mean change in NEI VFQ25 Questionnaire Score | Scores from NEI VFQ25 questionnaire will be assessed and compared | Baseline, 1 week, 1 month, 2 months, 3 months, and 6 months. | |
Secondary | Mean change in VisQoL scores | Scores from VisQoL questionnaire will be assessed and compared | Baseline, 1 week, 1 month, 2 months, 3 months, and 6 months. | |
Secondary | Mean change in wavefront aberrations | Mean deviation (MD) of wavefront aberrations is assessed by Nidek OPD Scan III test | Baseline, 1 week, 1 month, 2 months, 3 months, and 6 months. | |
Secondary | Mean change in ocular surface and tear-film | Mean deviation (MD) of ocular surface and tear-film parameters is assessed by Oculus Keratographer test | Baseline, 1 week, 1 month, 2 months, 3 months, and 6 months. | |
Secondary | Mean change in vessel density | Mean deviation (MD) of vessel density is assessed by Spectralis OCT2, Heidelberg-Engineering test | Baseline, 1 week, 1 month, 2 months, 3 months, and 6 months. | |
Secondary | Side effects | Side effects are measured by a review of the participant's medical and ophthalmic history. | Baseline, 1 week, 1 month, 2 months, 3 months, and 6 months. | |
Secondary | Use of additional treatments (including laser) | Use of additional treatments (including laser) is assessed by the treating ophthalmologist | Day 1 through Month 6 | |
Secondary | People meeting driving standards | Percentage (%) of people meeting driving standards is assessed by an Esterman binocular visual field test | Baseline, 1 week, 1month, 2 months, 3 months, and 6 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01969708 -
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
|
Phase 3 | |
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
Completed |
NCT01231633 -
Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)
|
N/A | |
Terminated |
NCT00969293 -
Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion
|
Phase 1 | |
Completed |
NCT03981549 -
Treatment of Central Retinal Vein Occlusion Using Stem Cells Study
|
Phase 1/Phase 2 | |
Completed |
NCT02274259 -
Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen
|
Phase 4 | |
Completed |
NCT01360385 -
Retinal Ischemia in Central Retinal Vein Occlusion, and the Effects of Treatment With Intravitreal Ranibizumab
|
N/A | |
Not yet recruiting |
NCT00383773 -
Retinal Endo Vascular Surgery for Central Retinal Vein Occlusion
|
N/A | |
Completed |
NCT00952614 -
A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion
|
N/A | |
Withdrawn |
NCT03417401 -
Surgical Stabilizer Assisted RVC With rtPA for CRVO
|
Phase 1 | |
Completed |
NCT01976312 -
Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)
|
Phase 3 | |
Completed |
NCT01724554 -
Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion
|
Phase 1/Phase 2 | |
Completed |
NCT01471691 -
Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01011374 -
Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion
|
Phase 1 | |
Completed |
NCT03223714 -
Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion
|
Phase 3 | |
Recruiting |
NCT01827722 -
Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion
|
Phase 4 | |
Completed |
NCT00906685 -
Bevacizumab for Central Retinal Vein Occlusion Study
|
Phase 3 | |
Active, not recruiting |
NCT04793100 -
Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO) in Patients With or Without Intravitreal Aflibercept Injections
|
N/A | |
Recruiting |
NCT02405741 -
Hyperbaric Chamber for Central Retinal Vein Occlusion (CRVO) Patients
|
Phase 2 | |
Recruiting |
NCT01348633 -
Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye
|
N/A |